Evidence map›Paper›PMID 27089331›Full record

ReviewInternational journal of molecular sciences2016

NAFLD and Chronic Kidney Disease.

Morgan Marcuccilli, Michel Chonchol

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06157125 (Assessment of the Association Between Metabolic Associated Fatty Liver Disease MFLD and Glomerulonephritis), which is not on this map. Cited by 100 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 1 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06157125 unknown statusnot on this mapstarted 2024, after this paper: background citation

Assessment of the Association Between Metabolic Associated Fatty Liver Disease MFLD and Glomerulonephritis

TypeobservationalSponsorAssiut UniversityRan2024 to 2025Enrolled100ConditionsAssessment of Patients With Biopsy Proven Primary Glomerulonephritis Above 18 Years of Age for MFLD Development
3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 1 synthesis or guideline pooled it, 201 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Observational
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Observational

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Morgan MarcuccilliDivision of Renal Diseases and Hypertension, University of Colorado Hospital, Aurora, CO 80045, USA. morgan.marcuccilli@ucdenver.edu.
Michel ChoncholDivision of Renal Diseases and Hypertension, University of Colorado Denver, 13199 East Montview Boulevard, Suite 495, Aurora, CO 80045, USA. michel.chonchol@ucdenver.edu.
University of Colorado Denver · USUniversity of Colorado Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries and it is now considered a risk factor for cardiovascular disease. Evidence linking NAFLD to the development and progression of chronic kidney disease (CKD) is emerging as a popular area of scientific interest. The rise in simultaneous liver-kidney transplantation as well as the significant cost associated with the presence of chronic kidney disease in the NAFLD population make this entity a worthwhile target for screening and therapeutic intervention. While several cross-sectional and case control studies have been published to substantiate these theories, very little data exists on the underlying cause of NAFLD and CKD. In this review, we will discuss the most recent publications on the diagnosis of NAFLD as well new evidence regarding the pathophysiology of NAFLD and CKD as an inflammatory disorder. These mechanisms include the role of obesity, the renin-angiotensin system, and dysregulation of fructose metabolism and lipogenesis in the development of both disorders. Further investigation of these pathways may lead to novel therapies that aim to target the NAFLD and CKD. However, more prospective studies that include information on both renal and liver histology will be necessary in order to understand the relationship between these diseases.

Indexed as

AnimalsFructoseHumansInflammationKidneyLipogenesisLiverNon-alcoholic Fatty Liver DiseaseRenal Insufficiency, ChronicRenin-Angiotensin SystemFructosechronic kidney diseaseinflammationnon-alcoholic fatty liver diseasenon-alcoholic steatohepatitisreview

Identifiers

PMID27089331
PMCPMC4849018
OpenAlexW2336813109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.